PARSIPPANY, N.J., Jan. 3, 2018 /PRNewswire/ -- Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the company will participate in the 5th Annual Dermatology Summit on January 7, 2018 at the Palace Hotel in San Francisco, Calif.
Michael Derby, co-founder and chief executive officer of Castle Creek, will present the company's clinical development pipeline and upcoming milestones during the Entrepreneurial Company Showcase session beginning at 5:05pm PST.
"As we advance our clinical development efforts, it is encouraging to see the unmet needs of people living with rare dermatologic conditions showcased at this year's Dermatology Summit," said Mr. Derby. "We are entering a year of tremendous growth, and have an important opportunity to support patients who may have been reluctant to seek medical help for their disease due to a historical lack of treatment options."
Castle Creek's lead product candidate, a topical diacerein 1% ointment (CCP-020), is currently being evaluated in the Phase 3 DELIVERS study for the treatment of epidermolysis bullosa simplex (EBS), a rare genetic connective tissue disorder that leads to extremely fragile skin resulting in mild to severe blistering, skin erosion and peeling of the epidermis layers in response to minor injury or friction.
The Annual Dermatology Summit brings together members of the financial community and business leaders from established and emerging companies in the dermatology space to help foster investment and partnerships in the next generation of dermatology companies and products. For more information, visit http://www.dermsummit.com/2018/ds/.
About Castle Creek Pharmaceuticals
Castle Creek Pharmaceuticals (CCP), part of the Paragon Biosciences portfolio of innovative biotech companies, is a privately held biopharmaceutical company developing innovative therapies for patients with rare, serious or debilitating dermatologic conditions. The company has a robust and diversified pipeline of late-stage products that have the potential to transform lives. For more information, please visit www.castlecreekpharma.com.
Media contact:
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com
SOURCE Castle Creek Pharmaceuticals